{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:19:26Z","timestamp":1785547166056,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Norwegian Research Center for Agonist Treatment of Substance Use Disorders"},{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40273-024-01442-3","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:02:19Z","timestamp":1729695739000},"page":"93-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5770-6698","authenticated-orcid":false,"given":"Prayash","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Thore","family":"Fadnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steinar","family":"Fosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Chalabianloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell Arne","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"10208","key":"1442_CR1","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379.","journal-title":"Lancet"},{"issue":"4","key":"1442_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000312","volume":"11","author":"YI Hser","year":"2017","unstructured":"Hser YI, Mooney LJ, Saxon AJ, et al. High mortality among patients with opioid use disorder in a large healthcare system. J Addict Med. 2017;11(4):315\u20139.","journal-title":"J Addict Med"},{"issue":"1","key":"1442_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13722-017-0071-3","volume":"12","author":"M Chetty","year":"2017","unstructured":"Chetty M, Kenworthy JJ, Langham S, et al. A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence. Addict Sci Clin Pract. 2017;12(1):6.","journal-title":"Addict Sci Clin Pract"},{"key":"1442_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.drugalcdep.2015.05.033","volume":"153","author":"K-C Chang","year":"2015","unstructured":"Chang K-C, Lu T-H, Lee K-Y, et al. Estimation of life expectancy and the expected years of life lost among heroin users in the era of opioid substitution treatment (OST) in Taiwan. Drug Alcohol Depend. 2015;153:152\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"1442_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000520185","volume":"28","author":"F Chalabianloo","year":"2021","unstructured":"Chalabianloo F, Ohldieck C, Haaland \u00d8A, et al. Effectiveness and safety of low-threshold opioid-agonist treatment in hard-to-reach populations with opioid dependence. Eur Addict Res. 2021;28(3):199\u2013209.","journal-title":"Eur Addict Res"},{"key":"1442_CR6","first-page":"39","volume":"10","author":"T Clausen","year":"2014","unstructured":"Clausen T. The Norwegian OMT program\u2014benefits and challenges. Norwegian J Pharm. 2014;10:39\u201342.","journal-title":"Norwegian J Pharm"},{"issue":"2","key":"1442_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1360-0443.2011.03637.x","volume":"107","author":"A Bukten","year":"2012","unstructured":"Bukten A, Skurtveit S, Gossop M, et al. Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction. 2012;107(2):393\u20139.","journal-title":"Addiction"},{"issue":"1","key":"1442_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000130","volume":"1","author":"I Skeie","year":"2011","unstructured":"Skeie I, Brekke M, Gossop M, et al. Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study. BMJ Open. 2011;1(1): e000130.","journal-title":"BMJ Open"},{"key":"1442_CR9","unstructured":"United Nations. Online World Drug Report 2023 - Latest data and trend analysis. 2023; Available from: https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/wdr-2023-online-segment.html."},{"key":"1442_CR10","unstructured":"Institute for Health Metrics and Evaluation. GBD Compare: Opioid Use Disorders. 2024, University of Washington"},{"issue":"9","key":"1442_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"TJ Santo","year":"2021","unstructured":"Santo TJ, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(9):979\u201393.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"1442_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13011-020-00309-y","volume":"15","author":"CF Aas","year":"2020","unstructured":"Aas CF, Vold JH, Skurtveit S, et al. Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. Subst Abuse Treat Prev Policy. 2020;15(1):68.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"1442_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12913-019-4382-9","volume":"19","author":"B Anne","year":"2019","unstructured":"Anne B, Stavseth MR, Clasuen T. From restrictive to more liberal: variations in mortality among patients in opioid maintenance treatment over a 12-year period. BMC Health Serv Res. 2019;19(1):553.","journal-title":"BMC Health Serv Res"},{"key":"1442_CR14","unstructured":"Nesse L, Lobmaier P, Skeie I et al. Tjuefem \u00e5r med legemiddelassisert rehabilitering (LAR). 2024, Senter for rus- og avhengighetsforskning, SERAF."},{"issue":"7","key":"1442_CR15","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jval.2020.12.023","volume":"24","author":"EN Onuoha","year":"2021","unstructured":"Onuoha EN, Leff JA, Schackman BR, et al. Economic evaluations of pharmacologic treatment for opioid use disorder: a systematic literature review. Value Health. 2021;24(7):1068\u201383.","journal-title":"Value Health"},{"issue":"1","key":"1442_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13011-019-0247-9","volume":"14","author":"J Reimer","year":"2019","unstructured":"Reimer J, Vogelmann T, Tr\u00fcmper D, Scherbaum N. Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment. Subst Abuse Treat Prev Policy. 2019;14(1):57.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1442_CR17","unstructured":"Swedish Agency for Health Technology Assessment and Assessment of Social Services. Cost effectiveness of pharmacological maintenance treatment of people with opioid use disorder. 2021: Stockholm, Sweden."},{"issue":"12","key":"1442_CR18","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1111\/add.16305","volume":"118","author":"AG Lim","year":"2023","unstructured":"Lim AG, Aas CF, \u00c7aglar ES, et al. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: an economic evaluation of the INTRO-HCV trial. Addiction. 2023;118(12):2424\u201339.","journal-title":"Addiction"},{"issue":"7","key":"1442_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1080\/13696998.2017.1325744","volume":"20","author":"J Kenworthy","year":"2017","unstructured":"Kenworthy J, Yi Y, Wright A, et al. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study. J Med Econ. 2017;20(7):740\u20138.","journal-title":"J Med Econ"},{"issue":"1","key":"1442_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M17-0611","volume":"168","author":"E Krebs","year":"2018","unstructured":"Krebs E, Enns B, Evans E, et al. Cost-effectiveness of publicly funded treatment of opioid use disorder in California. Ann Intern Med. 2018;168(1):10\u20139.","journal-title":"Ann Intern Med"},{"issue":"7","key":"1442_CR21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/add.14171","volume":"113","author":"N Bansback","year":"2018","unstructured":"Bansback N, Guh D, Oviedo-Joekes E, et al. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction. 2018;113(7):1264\u201373.","journal-title":"Addiction"},{"issue":"1","key":"1442_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jval.2020.10.010","volume":"24","author":"AL Avance\u00f1a","year":"2021","unstructured":"Avance\u00f1a AL, Prosser LA. Examining equity effects of health interventions in cost-effectiveness analysis: a systematic review. Value Health. 2021;24(1):136\u201343.","journal-title":"Value Health"},{"issue":"9","key":"1442_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11090","volume":"11","author":"M Connock","year":"2007","unstructured":"Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1\u2013171 (iii-iv).","journal-title":"Health Technol Assess"},{"key":"1442_CR24","unstructured":"Nesse L, Lobmaier P, Skeie I et al. Statusrapport 2022. F\u00f8rste \u00e5r med nye LAR-retningslinjer. 2023, Senter for rus- og avhengighetsforskning, SERAF"},{"key":"1442_CR25","unstructured":"Zin\u00f6cker S, Shrestha M, N\u00e6ss GE and Korn\u00f8r H. Effekter av legemiddelassistert rehabilitering sammenliknet med ikke-medikamentell behandling av opioidavhengighet: En systematisk oversikt [Effects of opioid maintenance treatment versus no drug therapies for opioid dependence: a systematic review] 2020, Folkehelseinstituttet: Oslo"},{"key":"1442_CR26","unstructured":"Duns\u00e6d F, Kristensen \u00d8, Vederhus J-K et al. Standardised detoxification in cases of polydrug use. Tidsskriftet 2016."},{"issue":"4","key":"1442_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jsat.2011.06.006","volume":"41","author":"A Bukten","year":"2011","unstructured":"Bukten A, Skurtveit S, Stangeland P, et al. Criminal convictions among dependent heroin users during a 3-year period prior to opioid maintenance treatment: a longitudinal national cohort study. J Subst Abuse Treat. 2011;41(4):407\u201314.","journal-title":"J Subst Abuse Treat"},{"key":"1442_CR28","doi-asserted-by":"publisher","DOI":"10.5324\/nje.v29i1-2.4047","author":"I Odsbu","year":"2021","unstructured":"Odsbu I, Mahic M, Skurtveit S, et al. An 11-year nationwide registry-linkage study of opioid maintenance treatment in pregnancy in Norway. Norsk Epidemiologi. 2021. https:\/\/doi.org\/10.5324\/nje.v29i1-2.4047.","journal-title":"Norsk Epidemiologi"},{"issue":"8","key":"1442_CR29","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/add.14188","volume":"113","author":"M Hickman","year":"2018","unstructured":"Hickman M, Steer C, Tilling K, et al. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Addiction. 2018;113(8):1461\u201376.","journal-title":"Addiction"},{"issue":"1","key":"1442_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12962-021-00303-6","volume":"19","author":"JH Vibeto","year":"2021","unstructured":"Vibeto JH, Vallersnes OM, Dobloug A, et al. Treating patients with opioid overdose at a primary care emergency outpatient clinic: a cost-minimization analysis. Cost Eff Resour Alloc. 2021;19(1):48.","journal-title":"Cost Eff Resour Alloc"},{"key":"1442_CR31","unstructured":"Norwegian Medical Products Agency. Submission guidelines for single technology assessment of medicinal products. 2023."},{"issue":"1","key":"1442_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2165\/00019053-200523010-00007","volume":"23","author":"AH Harris","year":"2005","unstructured":"Harris AH, Gospodarevskaya E, Ritter AJA. randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005;23(1):77\u201391.","journal-title":"Pharmacoeconomics"},{"key":"1442_CR33","unstructured":"Statistic Norway. Inflation calculator. 2024; Available from: https:\/\/www.ssb.no\/en\/kalkulatorer\/priskalkulator."},{"key":"1442_CR34","unstructured":"Helsedirektoratet. Produktivitet i somatisk spesialisthelsetjeneste. 2023."},{"key":"1442_CR35","unstructured":"Helsedirektoratet. Produktivitet i psykisk helsevern og tverrfaglig spesialisert rusbehandling. 2023."},{"key":"1442_CR36","unstructured":"Helsedirektoratet. Innsatsstyrt finansiering (ISF) \u2013 regelverk. 2023; Available from: https:\/\/www.helsedirektoratet.no\/tema\/finansiering\/innsatsstyrt-finansiering-og-drg-systemet\/innsatsstyrt-finansiering-isf#regulations."},{"key":"1442_CR37","unstructured":"Helsedirektoratet. Regelverk for innsatsstyrt finansiering 2023 (ISF-regelverket). 2023."},{"key":"1442_CR38","unstructured":"Norwegian Medical Association. Normaltariff for fastleger og legevakt 2023-2024. 2023; Available from: https:\/\/normaltariffen.legeforeningen.no\/book\/Fastlegetariffen-2023-2024\/m-02."},{"key":"1442_CR39","unstructured":"Statens Legemiddelverk. Legemiddelvisning: Metadon Nordic drugs. Available from: https:\/\/www.legemiddelsok.no\/sider\/Legemiddelvisning.aspx?pakningId=5b8a9add-00fb-4d6c-886f-e58b9c354a87&searchquery=methadone&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0."},{"key":"1442_CR40","unstructured":"Statens Legemiddelverk. Legemiddelvisning: Subutex. Available from: https:\/\/www.legemiddelsok.no\/sider\/Legemiddelvisning.aspx?pakningId=c4c67716-6129-44e3-ac78-0e20f6c67060&searchquery=subutex&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0."},{"key":"1442_CR41","unstructured":"Statens Legemiddelverk. Legemiddelvisning: Suboxone. Available from: https:\/\/www.legemiddelsok.no\/sider\/Legemiddelvisning.aspx?pakningId=4bb0fcc1-2d2c-49dd-b00a-db86d3eaa7cb&searchquery=suboxone&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0."},{"key":"1442_CR42","unstructured":"Statens Legemiddelverk. Legemiddelvisning: Buvidal. Available from: https:\/\/www.legemiddelsok.no\/sider\/Legemiddelvisning.aspx?pakningId=d5b39585-9b41-48fc-a3a7-83732f28ce9b&searchquery=buvidal&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0."},{"issue":"11","key":"1442_CR43","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1080\/03007995.2022.2129230","volume":"38","author":"MH Pedersen","year":"2022","unstructured":"Pedersen MH, Dan\u00f8 A, Gibbons C, Jensen R. Administration and patient-incurred costs associated with opioid agonist treatment in Norway. Curr Med Res Opin. 2022;38(11):1959\u201365.","journal-title":"Curr Med Res Opin"},{"key":"1442_CR44","unstructured":"Statistic Norway. Offences and victims reported to the police, by group of offence. Absolute figures. 2023; Available from: https:\/\/www.ssb.no\/en\/sosiale-forhold-og-kriminalitet\/kriminalitet-og-rettsvesen\/statistikk\/anmeldte-lovbrudd-og-ofre."},{"key":"1442_CR45","unstructured":"Eggen FW, Gran B, Norberg-Schulz M and Steen JI. Samfunns\u00f8konomiske kostnader av kriminalitet. 2022."},{"key":"1442_CR46","unstructured":"Ara R and Wailoo A. NICE DSU Technical Support Document 12: The Use of Health State Utility Values in Decision Models. 2011."},{"key":"1442_CR47","unstructured":"Norwegian Ministry of Health and Care Services. Principles for priority setting in health care. 2017."},{"issue":"6","key":"1442_CR48","doi-asserted-by":"publisher","first-page":"e2219503","DOI":"10.1001\/jamanetworkopen.2022.19503","volume":"5","author":"EJ Tranv\u00e5g","year":"2022","unstructured":"Tranv\u00e5g EJ, Haaland \u00d8A, Robberstad B, Norheim OF. Appraising drugs based on cost-effectiveness and severity of disease in Norwegian drug coverage decisions. JAMA Netw Open. 2022;5(6):e2219503\u2013e2219503.","journal-title":"JAMA Netw Open"},{"key":"1442_CR49","unstructured":"Magnussen J, Aaserud M, Granaas T et al. P\u00e5 ramme alvor-Alvorlighet og prioritering. Department of Health (p. 71). English summary available from: https:\/\/www.regjeringen.no\/contentassets\/d5da48ca5d1a4b128c72fc5daa3b4fd8\/summary_the_magnussen_report_on_severity.pdf 2015."},{"issue":"1","key":"1442_CR50","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12913-019-4282-z","volume":"19","author":"AB Bech","year":"2019","unstructured":"Bech AB, Clausen T, Waal H, et al. Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study. BMC Health Serv Res. 2019;19(1):440.","journal-title":"BMC Health Serv Res"},{"key":"1442_CR51","unstructured":"Helse-og omsorgsdepartementet. P\u00e5 ramme alvor Alvorlighet og prioritering: Rapport fra arbeidsgruppe nedsatt av Helse-og omsorgsdepartementet. 2015."},{"key":"1442_CR52","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s40273-018-0697-3","volume":"36","author":"AJ Hatswell","year":"2018","unstructured":"Hatswell AJ, Bullement A, Briggs A, et al. Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models. Pharmacoeconomics. 2018;36:1421\u20136.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1442_CR53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1586\/14737167.2016.1159958","volume":"16","author":"DR Faleiros","year":"2016","unstructured":"Faleiros DR, \u00c1lvares J, Almeida AM, et al. Budget impact analysis of medicines: updated systematic review and implications. Exp Rev Pharmacoecon Outcomes Res. 2016;16(2):257\u201366.","journal-title":"Exp Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"1442_CR54","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.drugpo.2012.06.009","volume":"23","author":"JJG Wammes","year":"2012","unstructured":"Wammes JJG, Siregar AY, Hidayat T, et al. Cost-effectiveness of methadone maintenance therapy as HIV prevention in an Indonesian high-prevalence setting: a mathematical modeling study. Int J Drug Policy. 2012;23(5):358\u201364.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"1442_CR55","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","volume":"27","author":"BR Schackman","year":"2012","unstructured":"Schackman BR, Leff JA, Polsky D, et al. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27(6):669\u201376.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"1442_CR56","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.drugalcdep.2006.01.010","volume":"84","author":"E Warren","year":"2006","unstructured":"Warren E, Viney R, Shearer J, et al. Value for money in drug treatment: economic evaluation of prison methadone. Drug Alcohol Depend. 2006;84(2):160\u20136.","journal-title":"Drug Alcohol Depend"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01442-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01442-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01442-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T14:08:55Z","timestamp":1736604535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01442-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1442"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01442-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"26 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study and open access were funded by the Norwegian Research Centre for Agonist Treatment of Substance Use Disorders (NORCATS), with the Department of Addiction Medicine at Haukeland University Hospital in Bergen, Norway serving as the responsible institution. The content of the work is solely the responsibility of the authors and does not necessarily represent the official views of the funders.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The mortality rates used for the analyses were obtained using primary data and are not available due to data protection requirements. However, the aggregated mortality rates used for the analyses are provided within the article and supplementary materials. Similarly, all other input parameters used in the analyses were taken from published or publicly available sources and are available within the article and supplementary materials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The study was approved by the Regional Committee for Medical and Health Research Ethics in South-East Norway (approval no. 28499).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"P.C. contributed to the study design and literature search, constructed the model, performed the analyses, and wrote the first draft of the manuscript. The supervision role was undertaken by K.A.J. S.F. contributed to approval, collection, and interpretation of mortality data. P.C., L.T.F., F.C., and K.A.J. contributed to conceptualization of the study, study design, collection and interpretation of data, and critical revision of previous versions of manuscript. All authors revised, read, and approved the final manuscript for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}